Skip to content

Exploration of the therapeutic effects of P8 bionic electrical stimulation on thin endometrium

Exploration of the therapeutic effects of P8 bionic electrical stimulation on thin endometrium

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116265
Enrollment
Unknown
Registered
2026-01-07
Start date
2022-07-08
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thin endometrium

Interventions

Control Group:Patients in the control group received a standard hormone replacement therapy (HRT) protocol for a total of three treatment cycles. The first two cycles served as pretreatment: starting
or ? Endometrial thickness remained <8 mm after 20 days of HRT. Luteal phase support consisted of intramuscular progesterone injection (60 mg/day). Blastocyst transfer was scheduled for the 6th day af
Experimental Group:Patients in the experimental group received the identical endometrial preparation protocol as the control group, combined with P8 biomimetic electrical stimulation. The specific reg

Sponsors

The Second Nanning People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
24 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Intended cryopreserved embryo transfer; 2. Previous ultrasound monitoring revealed endometrial thickness less than 7mm on the day of natural luteinising hormone surge during two cycles.

Exclusion criteria

Exclusion criteria: 1. Oligo-ovulation or anovulation; 2. Congenital reproductive tract malformations or congenital gonadal dysgenesis; 3. Uterine organic pathologies: uterine leiomyoma, adenomyosis, endometrial polyps, intrauterine adhesions, submucosal myoma, genital tuberculosis, etc.; 4.Thrombotic diseases or thrombophilia; 5.Acute genital tract infections or systemic infectious diseases; 6. Malignancy or failure of major organ systems; 7.Presence of a cardiac pacemaker; 8.Other organic pathologies of the reproductive system, including cervical intraepithelial neoplasia (CIN) grade II or higher; 9. Severe communicable diseases or epilepsy; 10. Incomplete clinical data or inability to adhere to the treatment protocol.

Design outcomes

Primary

MeasureTime frame
Endometrial thickness;

Secondary

MeasureTime frame
Uterine artery blood flow parameters;The clinical pregnancy rate achieved after FET;

Countries

China

Contacts

Public ContactYing Huang

The Second Nanning People's Hospital

huangyinggx@126.com+86 771 480 8332

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026